India’s pharmaceutical industry, often hailed as the “pharmacy of the world”, is confronting one of its most serious external challenges in recent years. The announcement by the United States in September 2025 of a 100% tariff on branded and patented pharmaceutical imports, aimed at encouraging domestic manufacturing, has injected uncertainty into global medicine supply chains. Although generic drugs have been spared for now, the move has exposed structural vulnerabilities in India’s export-dependent pharma model and raised fundamental questions about strategic autonomy, diversification and long-term resilience.
Month: Current Affairs - January 03, 2026
Category: